MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijrobp.2022.09.075

Медицинская библиотека · International journal of radiation oncology, biology, physics · 2022

External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.

Patel Sagar A, Ma Ting Martin, Wong Jessica K, Stish Bradley J, Dess Robert T, Pilar Avinash, Reddy Chandana, Wedde Trude B, Lilleby Wolfgang A, Fiano Ryan, Merrick Gregory S, Stock Richard G, Demanes D Jeffrey, Moran Brian J, Tran Phuoc T, Krauss Daniel J, Abu-Isa Eyad I, Pisansky Thomas M, Choo C Richard, Song Daniel Y, Greco Stephen, Deville Curtiland, DeWeese Theodore L, Tilki Derya, Ciezki Jay P, Karnes R Jeffrey, Nickols Nicholas G, Rettig Matthew B, Feng Felix Y, Berlin Alejandro, Tward Jonathan D, Davis Brian J, Reiter Robert E, Boutros Paul C, Romero Tahmineh, Horwitz Eric M, Tendulkar Rahul D, Steinberg Michael L, Spratt Daniel E, Xiang Michael, Kishan Amar U

Многоцентровое исследованиеСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: Very-high-risk (VHR) prostate cancer (PC) is an aggressive subgroup with high risk of distant disease progression. Systemic treatment intensification with abiraterone or docetaxel reduces PC-specific mortality (PCSM) and distant metastasis (DM) in men receiving external beam radiation therapy (EBRT) with androgen deprivation therapy (ADT). Whether prostate-directed treatment intensification with the addition of brachytherapy (BT) boost to EBRT with ADT improves outcomes in this group is unclear.

METHODS AND MATERIALS: This cohort study from 16 centers across 4 countries included men with VHR PC treated with either dose-escalated EBRT with ≥24 months of ADT or EBRT + BT boost with ≥12 months of ADT. VHR was defined by National Comprehensive Cancer Network (NCCN) criteria (clinical T3b-4, primary Gleason pattern 5, or ≥2 NCCN high-risk features), and results were corroborated in a subgroup of men who met Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trials inclusion criteria (≥2 of the following: clinical T3-4, Gleason 8-10, or PSA ≥40 ng/mL). PCSM and DM between EBRT and EBRT + BT were compared using inverse probability of treatment weight-adjusted Fine-Gray competing risk regression.

RESULTS

Among the entire cohort, 270 underwent EBRT and 101 EBRT + BT. After a median follow-up of 7.8 years, 6.7% and 5.9% of men died of PC and 16.3% and 9.9% had DM after EBRT and EBRT + BT, respectively. There was no significant difference in PCSM (sHR, 1.47 [95% CI, 0.57-3.75]; P = .42) or DM (sHR, 0.72, [95% CI, 0.30-1.71]; P = .45) between EBRT + BT and EBRT. Results were similar within the STAMPEDE-defined VHR subgroup (PCSM: sHR, 1.67 [95% CI, 0.48-5.81]; P = .42; DM: sHR, 0.56 [95% CI, 0.15-2.04]; P = .38).

CONCLUSIONS

In this VHR PC cohort, no difference in clinically meaningful outcomes was observed between EBRT alone with ≥24 months of ADT compared with EBRT + BT with ≥12 months of ADT. Comparative analyses in men treated with intensified systemic therapy are warranted.

Для цитирования: Patel Sagar A, Ma Ting Martin, Wong Jessica K, Stish Bradley J, Dess Robert T, Pilar Avinash, Reddy Chandana, Wedde Trude B, Lilleby Wolfgang A, Fiano Ryan, Merrick Gregory S, Stock Richard G, Demanes D Jeffrey, Moran Brian J, Tran Phuoc T, Krauss Daniel J, Abu-Isa Eyad I, Pisansky Thomas M, Choo C Richard, Song Daniel Y, Greco Stephen, Deville Curtiland, DeWeese Theodore L, Tilki Derya, Ciezki Jay P, Karnes R Jeffrey, Nickols Nicholas G, Rettig Matthew B, Feng Felix Y, Berlin Alejandro, Tward Jonathan D, Davis Brian J, Reiter Robert E, Boutros Paul C, Romero Tahmineh, Horwitz Eric M, Tendulkar Rahul D, Steinberg Michael L, Spratt Daniel E, Xiang Michael, Kishan Amar U. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.. International journal of radiation oncology, biology, physics. 2022. DOI: 10.1016/j.ijrobp.2022.09.075.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.